The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Vupparapalli Chandra Sekhar Reddy & Vupparapalli Pavani
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Astal Laboratories Ltd has reported that non-promoter group individuals, Vupparapalli Chandra Sekhar Reddy and Vupparapalli Pavani, were allotted 17,50,000 equity shares on 14 January 2026 via preferential allotment. The allotment includes 2,50,000 shares to Chandra Sekhar Reddy through warrant conversion and 15,00,000 shares to Pavani (12,50,000 via share swap and 2,50,000 via warrant conversion). Combined post-allotment holding stands at 20,50,000 shares (4.86% of voting capital, up from 2.79% earlier). The company's total equity capital expanded nearly 4x from Rs. 10.77 crore (1.07 crore shares) to Rs. 42.22 crore (4.22 crore shares), indicating a large-scale preferential issue.
Existing shareholders face significant dilution as the equity base was expanded almost fourfold through this preferential allotment. The acquirers are just below the 5% SAST disclosure threshold at 4.86%, meaning further acquisitions would trigger open offer obligations, which shareholders should monitor closely.